Hypertension-Related Renal Injury: A Major Contributor to End-Stage Renal Disease

https://doi.org/10.1016/S0272-6386(12)70183-XGet rights and content
Under a Creative Commons license
open archive

The US Renal Data System Annual Report reveals that 57% of new cases of end-stage renal disease are attributed to hypertensive nephropathy and diabetic nephropathy. Analyses of the data on serum creatinine from the Multiple Risk Factor Intervention Trial confirms that one in 20 of the hypertensive men exhibits a rate of decline in renal function that equals or exceeds 3% per year, the rate of loss being greater in older men, black men, and men with higher baseline blood pressure. Effective blood pressure treatment with maintenance of diastolic blood pressure below 95 mm Hg protected renal function in non-blacks but not in blacks, despite comparable blood pressure reduction in blacks. A longitudinal study of a diabetic cohort (n = 131) revealed that hypertension, plasma angiotensin II, and aldosterone are independent predictors of accelerated loss of renal function in diabetic nephropathy, possibly aggravated by diuretic usage as part of the anti hypertensive regimen in diabetic nephropathy. No significant loss of renal function could be documented in those individuals whose blood pressure was adequately controlled (systolic blood pressure, <140 mm Hg). These findings provide emphasis for the importance of adequate blood pressure control in both essential hypertension and hypertension associated with diabetes mellitus. They also provide support for the proposal that careful blood pressure control offers promise for reducing the incidence of end-stage renal disease in both hypertensive nephropathy and diabetic nephropathy.

Index Words

Hypertension
diabetes mellitus
end-stage renal disease
reciprocal creatinine
renal function
cholesterol
angiotensin II
aldosterone
prevention

Cited by (0)

Supported in part by USPHS Grants No. HL3303, HL20455, RR00722, RR00035, and DK 39885; The Irving Blum Memorial Fund; The Singley-Welty Diabetes Research Fund; and the Endowment Fund of the Good Samaritan Hospital.